Israeli multinational pharmaceutical company specializing in generic drugs, branded drugs, and active pharmaceutical ingredients; the largest generic drug manufacturer in the world, ranks 26th among largest pharmaceutical companies globally.
Clinical Trials
86
85 active
Approvals
8
Total approvals
Agencies
1
Regulatory bodies
Founded
1935
Active, not recruiting
85
98.8%
Completed
1
1.2%
- The FDA approved Teva's DEGEVMA (denosumab-adet) as a biosimilar to Xgeva across all reference indications, including bone complications from advanced cancer. - Approval was based on a totality of evidence showing no clinically meaningful differences from Xgeva in safety, purity and potency. - DEGEVMA is Teva's second FDA-approved biosimilar of 2026, following PONLIMSI in March, forming a denosumab portfolio spanning Xgeva and Prolia indications. - Teva plans to launch DEGEVMA and PONLIMSI in the U.S. in the coming months; DEGEVMA is already approved in the European Union.
- Russia's Federal Antimonopoly Service is examining whether Teva and Grotex launched apixaban products while Pfizer's Russian patent remained in force. - The proceedings cover Teva's Apixanta and Grotex's Apiklis, which complainants say entered commercial circulation before the original patent expired. - The patent at issue expires in February 2027, and FAS will assess conduct under Article 14.5 of Russia's competition law on intellectual property.
- Post hoc analysis of the Phase 3 SOLARIS open-label period found 231 of 411 participants (56%) receiving TEV-'749 achieved clinical stabilization, with only 10 (4%) subsequently relapsing. - Among 183 participants treated with TEV-'749 for six months or longer, 39 (21%) met criteria for remission based on sustained PANSS item scores. - Population pharmacokinetic simulations showed that starting TEV-'749 one day after the last oral or short-acting intramuscular olanzapine dose kept exposures within established therapeutic ranges. - Teva expects an FDA decision on TEV-'749 in Q4 2026, and the European Medicines Agency accepted the Marketing Authorization Application in May 2026.
- Teva Pharmaceuticals and the Trump Administration announced a shared commitment to lower the cost of select medicines for American patients covered by Medicaid. - If finalized, the agreement would align U.S. Medicaid pricing for select medicines with leading developed markets through the GENEROUS framework. - The deal would include a prospective Most-Favored-Nation (MFN) commitment for future innovative product launches and a dedicated reserve of certain active pharmaceutical ingredients (API). - Teva says the agreement would support continued investment in scientific innovation and U.S. pharmaceutical manufacturing capabilities.
- Teva announced a stalking horse bid to acquire BioXcel Therapeutics' dexmedetomidine sublingual film (BXCL501/IGALMI) through a court-supervised bankruptcy sale process. - The investigational film is under FDA review for at-home treatment of agitation associated with schizophrenia or bipolar I or II disorder, with a PDUFA date of November 14, 2026. - The transaction carries an upfront payment of $57.5 million plus up to $67.5 million in contingent payments, and remains subject to bankruptcy court approval and potential higher bids. - If approved, the product could become the first FDA-approved at-home treatment for this condition, addressing a meaningful unmet need in psychiatry.
- Moody's Ratings upgraded Teva's corporate credit rating to Baa3 from Ba1, achieving investment-grade status with a stable outlook on August 11, 2026. - The upgrade reflects Teva's successful growth strategy execution, including innovative product performance, pipeline expansion, and continued debt reduction supported by earnings growth. - This milestone follows Fitch Ratings' upgrade in May 2026, further strengthening Teva's credit standing and supporting eligibility for leading fixed-income indices. - CFO Eli Kalif stated the upgrade validates years of disciplined execution and enhances financial flexibility for continued investment in growth and innovation.
- Teva Pharmaceutical Industries and ARC Innovation at Sheba Medical Center signed a collaboration agreement to help Israeli health tech startups scale from pilots to global markets. - The partnership focuses on three areas: startup access to both organizations, clinical R&D collaboration, and logistics/operations including cold-chain and supply-chain challenges. - Both organizations won Israel Innovation Authority grants in December, which accelerated discussions and created converging paths for the collaboration. - A joint steering committee will meet quarterly with project budgets set individually, ranging from tens of thousands to millions of dollars.
- Biolojic Design earned a milestone payment from Teva as TEV-325, an AI-designed multibody targeting IL-13 and TSLP, achieved a preclinical milestone for treating TH2-driven inflammatory diseases. - TEV-325 represents a novel multibody design that can bind to either IL-13 or TSLP cytokines, potentially adapting to different disease states in conditions like asthma and atopic dermatitis. - The compound could become the second multibody and third AI-designed molecule from Biolojic's platform to enter clinical trials, with Teva planning to initiate clinical studies in 2027. - This milestone demonstrates AI's potential to solve clinical problems that conventional antibody technologies have struggled with for years.
- Teva Pharmaceutical Industries Ltd. has announced its intention to issue $2 billion (equivalent) of senior notes through its special purpose finance subsidiaries in both EUR and USD denominations. - The proceeds will primarily fund tender offers to purchase existing senior notes due between 2026 and 2031, with any remaining funds allocated to repay outstanding debt upon maturity or earlier redemption. - The notes will be unsecured senior obligations of the issuers and unconditionally guaranteed on a senior basis by Teva, reflecting the company's ongoing debt management strategy.
